Now showing items 1-20 of 24

    • Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. 

      Rini, BI; Dorff, TB; Elson, P; Rodriguez, CS; Shepard, D; Wood, L; Humbert, J; Pyle, L; Wong, Y-N; Finke, JH; Rayman, PA; Larkin, JMG; Garcia, JA; Plimack, ER (2016-09)
      A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases. Because of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit from initial active ...
    • Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. 

      Yost, S; de Wolf, B; Hanks, S; Zachariou, A; Marcozzi, C; Clarke, M; de Voer, R; Etemad, B; Uijttewaal, E; Ramsay, E; Wylie, H; Elliott, A; Picton, S; Smith, A; Smithson, S; Seal, S; Ruark, E; Houge, G; Pines, J; Kops, GJPL; Rahman, N (2017-07)
      Through exome sequencing, we identified six individuals with biallelic loss-of-function mutations in TRIP13. All six developed Wilms tumor. Constitutional mosaic aneuploidies, microcephaly, developmental delay and seizures, ...
    • Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. 

      Stewart, GD; Aitchison, M; Bex, A; Larkin, J; Lawless, C; Méjean, A; Nathan, P; Oades, G; Patard, J-J; Paul, J; Ravaud, A; Escudier, B; Renal Cross Channel Group (2017-06)
      Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting ...
    • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-12)
      The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
    • Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. 

      Gravis, G; Chanez, B; Derosa, L; Beuselinck, B; Barthelemy, P; Laguerre, B; Brachet, P-E; Joly, F; Escudier, B; Harrison, DJ; Laird, A; Vasudev, N; Ralph, C; Larkin, J; Lote, H; Salem, N; Walz, J; Thomassin, J; Sfumato, P; Stewart, GD; Boher, JM; Renal Cross Channel Group (2016-04)
      Glandular metastases (GMs) (pancreas, breast, parotid, thyroid, or contralateral adrenal) are rare in metastatic clear cell renal cell carcinoma (mccRCC). In a multicenter study we have assessed outcome from mccRCC with ...
    • Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. 

      Machiela, MJ; Hofmann, JN; Carreras-Torres, R; Brown, KM; Johansson, M; Wang, Z; Foll, M; Li, P; Rothman, N; Savage, SA; Gaborieau, V; McKay, JD; Ye, Y; Henrion, M; Bruinsma, F; Jordan, S; Severi, G; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Mannisto, S; Weinstein, S; Clark, PE; Edwards, TE; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Gaziano, JM; Sesso, HS; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Colli, LM; Sampson, JN; Besse, C; Blanche, H; Boland, A; Burdette, L; Prokhortchouk, E; Skryabin, KG; Yeager, M; Mijuskovic, M; Ognjanovic, M; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Bueno-de-Mesquita, HB; Canzian, F; Duell, EJ; Ljungberg, B; Sitaram, RT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Larkin, J; Choueiri, TK; Lathrop, GM; Teh, BT; Deleuze, J-F; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ; Scelo, G; Purdue, MP (2017-11)
      BACKGROUND:Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings. OBJECTIVE:We performed an ...
    • Genome-wide association study identifies multiple risk loci for renal cell carcinoma. 

      Scelo, G; Purdue, MP; Brown, KM; Johansson, M; Wang, Z; Eckel-Passow, JE; Ye, Y; Hofmann, JN; Choi, J; Foll, M; Gaborieau, V; Machiela, MJ; Colli, LM; Li, P; Sampson, JN; Abedi-Ardekani, B; Besse, C; Blanche, H; Boland, A; Burdette, L; Chabrier, A; Durand, G; Le Calvez-Kelm, F; Prokhortchouk, E; Robinot, N; Skryabin, KG; Wozniak, MB; Yeager, M; Basta-Jovanovic, G; Dzamic, Z; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Baglietto, L; Boeing, H; Khaw, K-T; Weiderpass, E; Ljungberg, B; Sitaram, RT; Bruinsma, F; Jordan, SJ; Severi, G; Winship, I; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Männistö, S; Weinstein, S; Clark, PE; Edwards, TL; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Michael Gaziano, J; Sesso, HD; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Teh, BT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Henrion, M; Larkin, J; Barman, P; Leibovich, BC; Choueiri, TK; Mark Lathrop, G; Rothman, N; Deleuze, J-F; McKay, JD; Parker, AS; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ (2017-06-09)
      Previous genome-wide association studies (GWAS) have identified six risk loci for renal cell carcinoma (RCC). We conducted a meta-analysis of two new scans of 5,198 cases and 7,331 controls together with four existing ...
    • Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. 

      Crusz, SM; Tang, YZ; Sarker, S-J; Prevoo, W; Kiyani, I; Beltran, L; Peters, J; Sahdev, A; Bex, A; Powles, T; Gerlinger, M (2016-11-14)
      Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the same patient.We ...
    • How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. 

      Bracarda, S; Negrier, S; Casper, J; Porta, C; Schmidinger, M; Larkin, J; Gross Goupil, M; Escudier, B (2017-03)
      Currently, sunitinib is a standard of care in first-line treatment for metastatic renal cell carcinoma (mRCC). However, with the standard 4/2 schedule (sunitinib 50 mg/day; 4 consecutive weeks on treatment; 2 weeks' rest), ...
    • The impact of 2D cine MR imaging parameters on automated tumor and organ localization for MR-guided real-time adaptive radiotherapy. 

      Menten, MJ; Fast, MF; Wetscherek, A; Rank, CM; Kachelrieß, M; Collins, DJ; Nill, S; Oelfke, U (2018-11-22)
      2D cine MR imaging may be utilized to monitor rapidly moving tumors and organs-at-risk for real-time adaptive radiotherapy. This study systematically investigates the impact of geometric imaging parameters on the ability ...
    • Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. 

      Turajlic, S; Litchfield, K; Xu, H; Rosenthal, R; McGranahan, N; Reading, JL; Wong, YNS; Rowan, A; Kanu, N; Al Bakir, M; Chambers, T; Salgado, R; Savas, P; Loi, S; Birkbak, NJ; Sansregret, L; Gore, M; Larkin, J; Quezada, SA; Swanton, C (2017-08)
      The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift ...
    • Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. 

      O'Reilly, A; Larkin, J (2017-03)
      In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents have ...
    • Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. 

      Little, RA; Jamin, Y; Boult, JKR; Naish, JH; Watson, Y; Cheung, S; Holliday, KF; Lu, H; McHugh, DJ; Irlam, J; West, CML; Betts, GN; Ashton, G; Reynolds, AR; Maddineni, S; Clarke, NW; Parker, GJM; Waterton, JC; Robinson, SP; O'Connor, JPB (2018-09)
      Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. ...
    • MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. 

      Trevisani, F; Ghidini, M; Larcher, A; Lampis, A; Lote, H; Manunta, P; Alibrandi, MTS; Zagato, L; Citterio, L; Dell'Antonio, G; Carenzi, C; Capasso, G; Rugge, M; Rigotti, P; Bertini, R; Cascione, L; Briganti, A; Salonia, A; Benigni, F; Braconi, C; Fassan, M; Hahne, JC; Montorsi, F; Valeri, N (2016-11)
      A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease has ...
    • Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI. 

      Robinson, SP; Boult, JKR; Vasudev, NS; Reynolds, AR (2017-08)
      Antiangiogenic therapy is efficacious in metastatic renal cell carcinoma (mRCC). However, the ability of antiangiogenic drugs to delay tumor progression and extend survival is limited, due to either innate or acquired drug ...
    • Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. 

      Little, SE; Bax, DA; Rodriguez-Pinilla, M; Natrajan, R; Messahel, B; Pritchard-Jones, K; Vujanic, GM; Reis-Filho, JS; Jones, C (2007-08)
      Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase overexpressed in a variety of human malignancies, against which targeted therapies have shown efficacy in lung and brain tumors. Clinical responses to ...
    • Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. 

      Muselaers, CHJ; Boers-Sonderen, MJ; van Oostenbrugge, TJ; Boerman, OC; Desar, IME; Stillebroer, AB; Mulder, SF; van Herpen, CML; Langenhuijsen, JF; Oosterwijk, E; Oyen, WJG; Mulders, PFA (2016-05)
      UNLABELLED:Despite advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC), there is still an unmet need in the treatment of this disease. A phase 2 radioimmunotherapy (RIT) trial with lutetium 177 ...
    • Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. 

      Hekman, MCH; Rijpkema, M; Aarntzen, EH; Mulder, SF; Langenhuijsen, JF; Oosterwijk, E; Boerman, OC; Oyen, WJG; Mulders, PFA (2018-09)
      Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study ...
    • Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. 

      Bridgeman, VL; Wan, E; Foo, S; Nathan, MR; Welti, JC; Frentzas, S; Vermeulen, PB; Preece, N; Springer, CJ; Powles, T; Nathan, PD; Larkin, J; Gore, M; Vasudev, NS; Reynolds, AR (2016-01)
      Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this ...
    • Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. 

      Grande, E; Glen, H; Aller, J; Argenziano, G; Lamas, MJ; Ruszniewski, P; Zamorano, JL; Edmonds, K; Sarker, S; Staehler, M; Larkin, J (2017-12)
      There are several second-line treatment options for patients with renal cell carcinoma after first-line failure of a tyrosine kinase inhibitor, especially with the recent approvals of cabozantinib, nivolumab, and the ...